BellBrook Labs, a leading provider of high throughput screening tools for the drug discovery industry, today announced that the U.S. Patent and Trademark Office issued a patent to BellBrook Labs the Transcreener™ HTS Assay platform.
Our proprietary Transcreener™ HTS Platform was developed to move more new targets into HTS more rapidly, and to streamline selectivity profiling within a target family. It relies on homogenous fluorescent immunodetection of nucleotides, including ADP, UDP, AMP and GMP, which are formed by thousands of cellular enzymes. Among these are group transferase families, such as kinases, ATPases and glycosyltransferases, that catalyze the covalent regulatory reactions that are central to cell signaling. Each Transcreener™ Assay provides a generic detection method for multiple enzyme families. This means that you can focus on evaluating new therapeutic strategies and optimizing lead molecules rather than on time-consuming assay development for individual targets. The Transcreener™ platform is unique in this regard; there is no other HTS platform with the potential to eliminate so much costly assay development for so many drug targets. Since introduction of the first Transcreener assays, the platform has been rapidly validated and adopted by pharmaceutical and biotechnology screening labs around the world.